17:56 , Jan 4, 2017 |  BC Innovations  |  Emerging Company Profile

Orum’s forum

  A major downside of therapeutic antibodies is that they can’t touch intracellular targets: the biologics are too large to diffuse across cell membranes on their own, and those entering cells via endocytosis degrade before...
07:00 , Mar 11, 2013 |  BioCentury  |  Product Development

Neomics' new tricks

Neomics Co. Ltd. is leveraging previously unknown functions of aminoacyl tRNA synthetases and their interacting proteins to build a pipeline of therapeutics and diagnostics for cancer. The most advanced program focuses on detecting and targeting...
07:00 , Jul 19, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Malaria Plasmodium falciparum lysyl-tRNA synthetase (Pfkrs1) In vitro and cell culture studies suggest inhibiting Pfkrs1 could help treat liver- and...